Eculizumab and its long-lasting form, ravulizumab, are monoclonal antibodies that bind to C5 and inhibit its cleavage by C5a, both approved for paroxysmal nocturnal hemoglobinuria [90]. Here, C5 is linked to paroxysmal nocturnal hemoglobinuria.